Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...
A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people ...
The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension ...
Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.
Nurse Justus Bell found relief from a painful, often undiagnosed skin disease at a UVA Health clinic, the only one of its ...
Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial ...
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...
Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results